Delivery Order SPE2DB22D9101-SPE2DB25FU7NF
- Not listed
- The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed-price delivery order contract valued at $1,315.80 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the provision of Mitosol 0.2mg kits, a pharmaceutical product, with a period of performance through April 4, 2024. This delivery order is issued under DMS Pharmaceutical Group's existing indefinite delivery vehicle (IDV) contract 4600082013 with the DLA, valued at up...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $5,263.24 by the Defense Logistics Agency on August 20, 2025, for the supply of Mitosol 0.2 mg kits. The delivery order carries an ultimate completion date of September 11, 2025, and no set-aside designation was used in the procurement. This award represents a continuation of the company's established role as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $23,684.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Mitosol 0.2 mg kits. The contract is firm fixed-price with an ultimate completion date of August 25, 2025. This delivery order was issued without a set-aside designation, leveraging the vendor's competitive position as a small business in federal procurement markets. Performance will be...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $1,315.80 by the Medical Supply Chain division of the Defense Logistics Agency on July 25, 2025. The delivery order, which is expected to be completed by August 14, 2025, covers the supply of Mitosol 0.2mg kits in quantities of three units. This award was issued without a set-aside designation, and the place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $5,263.24 to DMS Pharmaceutical Group Inc. for Mitosol 0.2 mg kits, with an ultimate completion date of September 12, 2025. This firm fixed-price delivery order was issued without a set-aside designation to the woman-owned small business pharmaceutical wholesaler, which is based in Park Ridge, Illinois and will perform the work at that same location. DMS Pharmaceutical Group Inc. operates under a larger Indefinite Delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $7,894.80 on September 15, 2025, for Mitosol 0.2 mg kits. This firm fixed-price delivery order, which must be completed by October 6, 2025, was issued by the Medical Supply Chain, a defense-focused federal agency. The contract carries no set-aside designation, allowing DMS Pharmaceutical Group to compete openly in the federal procurement...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $10,526.40 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of MITOSOL 0.2 MG KITS, a specialized pharmaceutical product, with a period of performance through November 2024. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract with the DLA under the SPE2DB program to provide a broad range of...
- The Defense Logistics Agency awarded a $1,315.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for Mitosol 0.2 mg kits, with an ultimate completion date of October 8, 2025. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA under the SPE2DB program, which...
- The Defense Logistics Agency awarded a delivery order valued at $5,263.24 to DMS Pharmaceutical Group Inc. for Mitosol 0.2 mg kits, with an ultimate completion date of August 8, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. The contract employs firm fixed-price pricing and represents a delivery order under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order valued at $1,315.80 to DMS Pharmaceutical Group Inc. for MITOSOL 0.2 mg kits, with an ultimate completion date of October 8, 2025. This firm fixed-price delivery order was issued without a set-aside designation to the woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. DMS Pharmaceutical Group Inc. will deliver the pharmaceutical product to its place of performance location in Park Ridge, IL. This delivery...
- SPE2DB22D9101Indefinite Delivery Contract
- SPE2DB22D9101-SPE2DB25FU7NFDelivery Order
The Defense Logistics Agency awarded a $3,947.40 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Mitosol 0.2 mg kits. The contract, issued on September 18, 2025, with an ultimate completion date of October 9, 2025, utilizes a firm fixed-price structure and carries no set-aside designation. This delivery order is part of DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at $499,999,999 and extending through November 2026, which enables the agency to procure an extensive range of pharmaceutical products supporting military health facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently delivering branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare sites. The company's robust contract portfolio with the DLA demonstrates its capability to fulfill specialized pharmaceutical requirements, including oncology treatments, vaccines, and other specialty medications. This particular delivery order for Mitosol kits represents routine procurement under the broader IDC vehicle, supporting the DLA's mission to provide comprehensive pharmaceutical support to military medical facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.9k | 9/18/25 |